Cambridge, Massachusetts-based Alnylam Pharmaceuticals released positive Phase III data from the ILLUMINATE-A clinical trial of lumasiran in the treatment of primary hyperoxaluria type 1 (PH1).

Amgen Inc. struck a research and development deal for the development of Advaxis Inc.’s pre-clinical immunotherapy treatment, ADXS-NEO.

Media Alert: Webinar on Improving Clinical Trial Performance – October 2015   WHAT: CRO Analytics will host an upcoming webinar in October, “QPIs: What They Are And How They Drive Your KPIs”. This webinar will review the key concepts surrounding clinical trial metrics malpractice, performance measurement, and Quality Performance Indicators (QPIs); all topics put forth […]